A recent research revealed that discontinuing GLP-1 drugs for diabetes may increase the risk of cardiac events, stroke, and may also lead to death.While these drugs, such as Ozempic, Victoza, ...

@2024 - All Right Reserved.

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity.

In people with type 2 diabetes in the world's richest countries, deaths from cardiovascular disease are declining while ...

GLP-1 RAs were first approved for youth with type 2 diabetes with liraglutide (Victoza) in 2019, followed by semaglutide (Wegovy) and dulaglutide (Trulicity) in 2022. Prior to these approvals, insulin ...